Gonitro is owned by Pohl Boskamp.
Gonitro contains Nitroglycerin.
Gonitro has a total of 1 drug patent out of which 0 drug patents have expired.
Gonitro was authorised for market use on 08 June, 2016.
Gonitro is available in powder;sublingual dosage forms.
The generics of Gonitro are possible to be released after 11 March, 2032.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9101592||POHL BOSKAMP||Stabilized granules containing glyceryl trinitrate|| |
(9 years from now)
Market Authorisation Date: 08 June, 2016
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic